V.I. GRIDNEV, YA.А. SOTSKAYA

 Saint Luka Lugansk State Medical University, Lugansk

Contact details:

Gridnev V.I. — post-graduate student of the Department of Internal Diseases

Address: 1g 50-letiya oborony Luganska St., 291045 Lugansk, Russian Federation, tel.: +7-959-191-80-52, e-mail: iam@vgridnev.ru

 The purpose — to evaluate the intestinal microbiota composition and the liver fibrosis severity in patients with chronic persistent hepatitis combined with irritable bowel syndrome.

Material and methods. The study included 63 people aged 19 to 59 y. o., 32 men (51%) and 31 women (49%). We determined the liver fibrosis degree by transient elastography using the LFP-5 sensor of the Mindray Hepatus 6 ultrasound system and assessed its severity using the METAVIR scale. Additionally, we determined the quantitative composition of the intestinal microbiota in all patients by the polymerase chain reaction method.

Results. The biochemical blood test revealed cytolytic and cholestatic syndrome, pigment and biosynthetic metabolism disorders in all patients suffering from chronic persistent hepatitis combined with irritable bowel syndrome. The quantification of the microbiota showed a decreased concentration of Bifidobacterium spp, Faecalibacterium prausnitzii and Enterococcus spp. The study revealed fibrotic liver changes in 35.3% of men and 39% of women.

Conclusion. Intestinal dysbiosis is associated with the onset and progression of liver cell damage, provoking the development of the liver fibrosis and cirrhosis. The correlation between the specific intestinal microbiota and the pathogenesis of liver fibrosis progression requires further study.

Key words: chronic hepatitis, dysbiosis, fibrosis, cirrhosis, microbiota

REFERENCES

1. Tilg H., Adolph T.E., Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Metab, 2022, vol. 34, pp. 1700–1718. DOI: 10.1016/j.cmet.2022.09.017
2. Aytbayev K.A., Murkamilov I.T., Fomin V.V. Liver diseases: the pathogenetic role of the intestinal microbiome and the potential of therapy for its modulation. Terapevticheskiy arkhiv, 2017, vol. 89, no. 8, pp. 120–128 (in Russ.).
3. Zhu X., Zhou Z., Pan X. Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023). Microbiol, 2024, vol. 15, p. 1342356. DOI: 10.3389/fmicb.2024.1342356
4. Cheng Z., Yang L., Chu H. The role of gut microbiota, exosomes, and their interaction in the pathogenesis of ALD. Adv. Res, 2025, vol. 72, pp. 353–367. DOI: 10.1016/j.jare.2024.07.002
5. Smith M.L., Wade J.B., Wolstenholme J., Bajaj J.S. Gut microbiome-brain-cirrhosis axis. Hepatology, 2024, vol. 80, pp. 465–485. DOI: 10.1097/HEP.0000000000000344
6. Liu S., Yang X. Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer. Cell. Infect. Microbiol, 2023, vol. 13, pp. 1140126. DOI: 10.3389/fcimb.2023.1140126
7. Akhmedova M.D., Sultonova G.Yu., Bektimirov A.M., Barinova A.N. The state of the intestinal microflora in patients with liver cirrhosis of viral etiology and correction of its treatment. VICH-infektsiya i immunosupressii, 2021, vol. 13, no. 1, pp. 97–105 (in Russ.).
8. Shu W., Shanjian C., Jinpiao L., Qishui O. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis. Hepatol, 2022, vol. 27, p. 100676. DOI: 10.1016/j.aohep.2022.100676
9. Fairfield B., Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep, 2020, vol. 3 (2), p. 100220. DOI: 10.1016/j.jhepr.2020.100220
10. Cheng Z., Chen Y., Schnabl B., Chu H., Yang L. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets. Adv. Res, 2024, vol. 59, pp. 173–187. DOI: 10.1016/j.jare.2023.06.009
11. Laivacuma S., Oblate O., Derovs A. Gut microbiota and the gut-liver axis in liver disease: from chronic viral hepatitis to cirrhosis, hepatocellular carcinoma, and microbiome-based therapies. Microorganisms, 2025, vol. 13, p. 1053. DOI: 10.3390/microorganisms13051053
12. Yan Y., Zeng J., Xing L., Li C. Extra- and intra-cellular mechanisms of hepatic stellate cell activation. Biomedicines, 2021, vol. 9, p. 1014. DOI: 10.3390/biomedicines9081014
13. Nguyen H.H., Fritzler M.J., Swain M.G. A review on biomarkers for the evaluation of autoimmune cholestatic liver diseases and their overlap syndromes. Mol. Med, 2022, vol. 2, p. 914505. DOI: 10.3389/fmmed.2022.914505
14. Anis M.A., Shahid Y., Majeed A.A., Abid S. Microbiome and gut-liver interactions: from mechanisms to therapies. World J. Gastroenterol, 2025, vol. 31, p. 111409. DOI: 10.3748/wjg.v31.i40.111409
15. Gudan A., Kozłowska-Petriczko K., Wunsch E., Bodnarczuk T., Stachowska E. Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease: what do we know in 2023? Nutrients, 2023, vol. 15, p. 1323. DOI: 10.3390/nu15061323
16. Chuaypen N., Jinato T., Avihingsanon A., Nookaew I., Tanaka Y., Tangkijvanich P. Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection. Rep, 2023, vol. 13, p. 14413. DOI: 10.1038/s41598-023-41664-7
17. Laivacuma S., Oblate O., Derovs A. Gut microbiota and the gut-liver axis in liver disease: from chronic viral hepatitis to cirrhosis, hepatocellular carcinoma, and microbiome-based therapies. Microorganisms, 2025, vol. 13, p. 1053. DOI: 10.3390/microorganisms13051053
18. Simon E., Călinoiu L.F., Mitrea L., Vodnar D.C. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients,2021, vol. 13, p. 2112. DOI: 10.3390/nu13062112
19. Safari Z., Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Mol. Life Sci, 2019, vol. 76, pp. 1541–1558. DOI: 10.1007/s00018-019-03011-w
20. Trebicka J., Macnaughtan J., Schnabl B., Shawcross D.L., Bajaj J.S. The microbiota in cirrhosis and its role in hepatic decompensation. Hepatol, 2021, vol. 75, pp. 67-S81. DOI: 10.1016/j.jhep.2020.11.013